Comment from Duke Health

Summary: Duke University expresses strong support for the FDA's Expedited Investigational New Drug (IND) Pilot Program, highlighting its own extensive infrastructure and expertise in early-phase drug development. They provide detailed recommendations on QRI qualification, pilot design, and funding to ensure the program effectively accelerates first-in-human clinical trials while maintaining safety and scientific rigor.